

Title page
Word count: 3850

1 **Title: Chemosensory dysfunctions induced by COVID-19 can persist**

2 **up to 7 months: A study of over 700 healthcare workers**

3 **Authors:** Nicholas **Bussière**¹; Jie **Mei**¹, PhD; Cindy **Lévesque-Boissonneault**¹, MSc; Mathieu

4 **Blais**^{2,3}, PhD; Sara **Carazo**⁴, MD, PhD; Francois **Gros-Louis**^{2,3}, PhD; Gaston **De Serres**⁴, MD,

5 PhD; Nicolas **Dupré**^{5,6}, MD, MSc, FRCP FAAN; Johannes **Frasnelli**¹, MD

6 ¹ Department of Anatomy, Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada

7 ² Axe Médecine régénératrice, CHU de Québec–Université Laval, Québec City, QC, Canada

8 ³ Faculty of Medicine, Department of Surgery, Université Laval, Québec City, QC, Canada

9 ⁴ Institut National de Santé Publique du Québec, Québec City, QC, Canada

10 ⁵ Faculty of Medicine, Department of Medicine, Université Laval, Québec City, QC, Canada

11 ⁶ Axe Neurosciences, CHU de Québec–Université Laval, Québec City, QC, Canada

12

13 **Correspondence to be sent to :**

14 Johannes Frasnelli MD,

15 Université du Québec à Trois-Rivières,

16 3351, boul. des Forges, C.P. 500,

17 Trois-Rivières, QC G9A 5H7 Canada

18 Email: johannes.a.frasnelli@uqtr.ca

19 **Abstract:**

20 Several studies have revealed either self-reported chemosensory alterations in large groups or
21 objective quantified chemosensory impairments in smaller populations of patients diagnosed
22 with COVID-19. However, due to the great variability in published results regarding COVID-19-
23 induced chemosensory impairments and their follow-up, prognosis for chemosensory functions
24 in patients with such complaints remains unclear. Our objective is to describe the various
25 chemosensory alterations associated with COVID-19 and their prevalence and evolution after
26 infection. A cross-sectional study of 704 healthcare workers with a RT-PCR confirmed SARS-
27 CoV-2 infection between 28/2/2020 and 14/6/2020 was conducted 3 to 7 months after onset of
28 symptoms. Data were collected with an online questionnaire. Outcomes included differences in
29 reported chemosensory self-assessment of olfactory, gustatory, and trigeminal functions across
30 time points and Chemosensory Perception Test scores from an easy-to-use at-home self-
31 administered chemosensory test. Among the 704 participants, 593 (84.2%) were women, the
32 mean (SD) age was 42 (12) years, and the questionnaire was answered on average 4.8 (0.8)
33 months after COVID-19. During COVID-19, a decrease in olfactory, gustatory, and trigeminal
34 sensitivities were reported by 81.3%, 81.5% and 48.0% respectively. Three to seven months
35 later, reduced sensitivity was still reported by 52.0%, 41.9% and 23.3% respectively.
36 Chemosensory Perception Test scores indicate that 19.5% of participants had objective olfactory
37 impairment. These data suggest a significant proportion of COVID-19 cases have persistent
38 chemosensory impairments at 3 to 7 months after their infection but the majority of those who
39 had completely lost their olfactory, gustatory, and trigeminal sensitivity have improved.

40

41 **Keywords:** COVID-19, anosmia, parosmia, long-term, taste, trigeminal system

42 **Introduction:**

43 Coronavirus disease-2019 (COVID-19) is an ongoing major public health challenge. Olfactory
44 dysfunction (OD) is a specific symptom that may affect approximately 60% of patients suffering
45 from COVID-19 (Spinato, Fabbris et al. 2020, von Bartheld, Hagen et al. 2020, Whitcroft and
46 Hummel 2020), and is now considered as a stronger indicator of COVID-19 than fever, cough
47 and shortness of breath (Gerkin, Ohla et al. 2021).

48 OD can be quantitative or qualitative. Quantitative OD is defined by a reduction of
49 olfactory sensitivity which can be either a complete (anosmia) or a partial (hyposmia) loss of
50 olfactory function (Hummel, Whitcroft et al. 2016). Qualitative OD describes an altered
51 perception of olfactory stimuli: For example, parosmia is defined as the perception of
52 qualitatively altered smells, and phantosmia is defined as the perception of a smell in the absence
53 of an objective odorant (Hummel, Whitcroft et al. 2016, Sjölund, Larsson et al. 2017). Overall,
54 the prevalence of OD in the general population is around 20% (Landis, Konnerth et al. 2004,
55 Yang and Pinto 2016), and all different forms of OD are associated with reduced quality of life
56 (Croy, Nordin et al. 2014). In addition to OD, COVID-19 also appears to affect other
57 chemosensory modalities, i.e., gustation and trigeminal function (Cooper, Brann et al. 2020,
58 Parma, Ohla et al. 2020).

59 Olfactory and other chemosensory dysfunctions may have detrimental effects. First,
60 affected individuals can expose themselves to harmful substances such as smoke, gas or spoiled
61 food (Gonzales and Cook 2007, Schiffman 2007). It may trigger dysfunctional nutritional
62 patterns like increased salt and sugar consumption, or anorexia (Mattes, Cowart et al. 1990,
63 Aschenbrenner, Hummel et al. 2008). Individuals with OD also have higher rates of anxiety and
64 depression (Croy, Nordin et al. 2014, Kohli, Soler et al. 2016). Moreover, a functioning olfactory

65 system may be a necessity in some workplaces, such as healthcare, where staff are required to
66 have the ability to detect and qualify the smell of urine, excrement, infected wounds or abnormal
67 smells of breath (Kelly 2012).

68 Investigation of the long-term effects of COVID-19 on chemosensory function is
69 hindered by the recent onset of the pandemic and other challenges: First, many studies on the
70 prevalence of OD during COVID include a relatively small number of participants (Hintschich,
71 Wenzel et al. 2020, Le Bon, Pisarski et al. 2020) or participants with severe forms of COVID-19
72 (Moein, Hashemian et al. 2020, Speth, Singer-Cornelius et al. 2020). Secondly, many studies on
73 the prevalence of OD during COVID-19 also include participants with an unclear diagnosis of
74 COVID-19, and/or self-diagnosis (Hopkins, Surda et al. 2020, Parma, Ohla et al. 2020). Lastly,
75 while individuals with anosmia can usually evaluate their olfactory function with accuracy
76 (Lötsch and Hummel 2019), this self-assessment is often challenging for individuals with
77 intermediate forms of OD (e.g., hyposmia) (Landis, Hummel et al. 2003). Finally, studies on
78 persistent post-COVID-19 OD in the past year have used various designs (objective measures
79 (Lechien, Chiesa-Estomba et al. 2021), semi-objective (Petrocelli, Cutrupi et al. 2021), or self-
80 reported (Havervall, Rosell et al. 2021, Hopkins, Surda et al. 2021) and collected data at varying
81 time intervals after onset of disease. For these reasons, to this date, no consensus has been
82 reached regarding the prevalence of post-COVID-19 OD (Xydakis, Albers et al.).

83 To comprehensively understand long-term olfactory, gustatory, and trigeminal alterations
84 after COVID-19, we analyzed questionnaire responses from a cohort of healthcare workers
85 infected with SARS-CoV-2 during the first wave of the pandemic (February - June 2020). We
86 also developed a Chemosensory Perception Test (CPT), a formal test employing common
87 household odorants and tastants to enable accessible yet accurate self-evaluation of

88 chemosensory functions remotely on a large scale. The CPT is particularly useful when in-person
89 testing is unsafe and testing a large group of participants at distance with mailable tests such as
90 the UPSIT (Doty, Shaman et al. 1984) is costly. Moreover, distance testing has been reported to
91 accurately monitor disease progression in at risk populations (Vaira, Hopkins et al. 2020, Weiss,
92 Attuquayefio et al. 2020).

93 **Materials and Methods:**

94

95 **Participants**

96 Participants were recruited from a Quebec healthcare worker cohort who have had SARS-CoV-2
97 infection between 28/2/2020 and 14/6/2020. They were part of a study from the Institut National
98 de Santé Publique du Québec and had agreed to be contacted for other research projects(Carazo
99 2021). Inclusion criteria were (1) RT-PCR confirmed COVID-19 (2) above 18 years of age, (3)
100 French or English speakers, (4) completed the online questionnaire, and (5) did not report of
101 other respiratory diseases (bacterial or viral infection, or/and allergies with rhinorrhea) within 2
102 weeks prior to questionnaire completion or chronic sinusitis (Figure 1).

103 This study was reviewed and approved by the research ethics board of the CHU
104 de Québec – Université Laval (MP-20-2021-5228) and all protocols were reviewed by an
105 independent Scientific Review Committee. This study also complies with the Declaration of
106 Helsinki for Medical Research Involving Human Subjects. All participants provided an online
107 informed consent prior to participation. The study received funding from the Fonds de recherche
108 du Québec-Santé. No compensation or incentive was offered for participation. Data were
109 collected from August 11 to October 29, 2020. Up to four attempts were made to reach by email
110 potential participants. At the time of data collection, participants were 3-7 months after the onset
111 of COVID-19 symptoms.

112

113 **Online questionnaire:**

114 All participants were asked to complete an online questionnaire which was adapted from the core
115 questionnaire of the Global Consortium on Chemosensory Research(Parma, Ohla et al. 2020).

116 Demographic information: In the first part of the questionnaire, demographic information
117 was collected from all participants. Participants were then instructed to provide medical history
118 and indicate the presence of specific COVID-19 symptoms (Figure 2).

119 Chemosensory self-assessment: Participants were asked to self-evaluate and report their
120 olfactory , gustatory, and trigeminal sensitivity using a 10-point visual analog scale (VAS;
121 Figure 2) for three timepoints: (1) before SARS-CoV-2 infection, (2) during SARS-CoV-2
122 infection and (3) at questionnaire completion. The specific definition of each chemosensory
123 modality was presented prior to self-evaluation of each chemosensory modality as follows:
124 Olfaction: *The following questions relate to your sense of smell (for example, sniffing flowers or*
125 *soap, or smelling garbage) but not the flavor of food in your mouth*; Gustation: *The following*
126 *questions are related to your sense of taste. For example, sweetness, sourness, saltiness,*
127 *bitterness experienced in the mouth*; Trigeminal: *The following questions are related to other*
128 *sensations in your mouth, like burning, cooling, or tingling. For example, chili peppers, mint*
129 *gum or candy, or carbonation*. Further, information on the presence of parosmia or phantosmia
130 following the infection (Landis, Frasnelli et al. 2010) and alterations in the 5 tastes (sweet, salty,
131 sour, bitter, umami) was collected.

132 Chemosensory Perception Test (CPT): Items commonly found in North American
133 households were used to assess participants' olfactory and gustatory functions, as odor intensity
134 is the best single predictor to classify individuals with normosmia (Parma, Hannum et al. 2021).
135 Participants had to smell three substances (peanut butter, jam/jelly, and coffee) and rate odor
136 intensity on a 10-point VAS (0: no smell at all; 10: very strong smell). We obtained olfactory
137 scores by averaging these ratings. Pilot data on a total of 93 participants show these scores to
138 accurately detect OD when compared to the Sniffin' Sticks (cut-off score: 6/10; sensitivity:

139 0.765; specificity: 0.895; Supplement 3). Participants were asked to prepare saline and sweet
140 water by dissolving respectively a teaspoon of salt or 3 teaspoons of sugar in a cup (250 mL) of
141 lukewarm water. Then, they were asked to taste saline and sweet water and to rate taste
142 intensities on a 10-point VAS. We obtained gustatory scores by averaging these ratings. An
143 ongoing study is comparing CPT gustatory scores with the Waterless-Empirical Taste Test -
144 Self-Administered (Doty, Wylie et al. 2021), but too few participants have been recruited to this
145 to establish its accuracy (Supplement 3).

146

147 **Statistical Analyses:**

148 A Python script (Python 3.7.5, Python Software Foundation, <https://www.python.org>) was used
149 to process raw questionnaire data and to calculate the number of participants reporting COVID-
150 19 symptoms, chronic conditions and recent respiratory illnesses. Processed data were analyzed
151 and visualized with SPSS 26.0 (Armonk, NY: IBM Corp), GraphPad Prism 8.3.1 (GraphPad
152 Prism Software, San Diego, CA) and Raincloud plots(Allen, Poggiali et al. 2021).

153 Parametric (ANOVA) or non-parametric (Friedman) tests were chosen depending on
154 whether normality assumption was fulfilled. To evaluate the effects of COVID-19 on *modality*
155 (olfactory, gustatory, and trigeminal) and *time* (prior to, during and after COVID-19 infection),
156 for *gender* (women, men), repeated measures (rm) ANOVA with age as a covariate were
157 computed. To disentangle interactions, separate rmANOVA were carried out for individual
158 modalities and timepoints with the same factors. Greenhouse-Geisser corrections were used for
159 sphericity and Tukey's multiple comparisons test were used for post-hoc comparisons.
160 Friedman's test was followed by Dunn's post-hoc test to correct for multiple comparisons. To
161 assess the correlation between self-reported olfactory, gustatory, and trigeminal abilities and

162 results of the CPT, Pearson correlation coefficient or Spearman's rank correlation coefficient
163 was used. For all statistical tests, alpha was set at 0.05. All results are expressed as mean (SD)
164 unless otherwise specified.

165 **Results:**

166

167 **Characteristics of participants:**

168 A total of 704 healthcare workers (593 (84.2%) women, mean age of 42.0 (SD:11.7, range 18 –
169 70) years were included. The questionnaire was completed on average 4.8 (SD: 0.8, range 3-7)
170 months after symptoms onset. COVID-19 symptoms reported by the 704 participants are listed in
171 Table 1.

172

173 **Quantitative disorders:**

174 Before COVID-19, average self-reported score was 9.0 (1.6), 9.2 (1.3) and 8.9 (1.9) of 10 for
175 olfaction, gustation and trigeminal function, respectively. Among participants, 0.9%, 0.7% and
176 1.8% respectively reported an absence of olfaction, gustation and trigeminal function (score 0;
177 Figure 3). During COVID-19, average self-reported score was 2.6 (3.6) for olfaction, 3.4 (3.6)
178 for gustation, and 7.0 (3.0) for trigeminal sensitivity. In the 704 participants, 51.1%, 33.5% and
179 5.7% reported absence of olfaction, gustation and trigeminal function. At time of questionnaire
180 completion, mean scores were 7.4 (2.5), 8.0 (2.2) and 8.5 (2.2) for olfaction, gustation and
181 trigeminal function respectively and absence of chemical senses was reported respectively by
182 1.4%, 0.7% and 2.3%. Weak correlations were found between the time since infection and the
183 self-reported olfactory and gustatory scores at questionnaire completion (olfaction: $\rho=0.11$;
184 gustation: $\rho=0.14$; both $P<.001$; trigeminal $\rho = .06$; $P=.11$).

185 Compared to the baseline chemosensory functions before COVID-19, 572 (81.3%), 574
186 (81.5) and 338 (48.0%) reported lower olfactory, gustatory, and trigeminal sensitivity during
187 COVID-19. Olfactory and gustatory dysfunction were present in similar proportions ($\chi^2(2,$

188 N=704) = 0.02, $P = .891$) and were different to trigeminal (olfaction: $\chi^2(2, N=704) = 174.81$
189 $P < .001$; gustation: $\chi^2(2, N=704) = 174.56$ $P < .001$). Three to seven months after the infection,
190 366 (52.0%), 295 (41.9%), 164 (23.3%) reported lower olfactory, gustatory, and trigeminal
191 sensitivity compared to before COVID-19 (Table 2). These proportions were significantly
192 different between all three chemosensory systems ($\chi^2(2, N=704) = 123.46$, $P < .001$).

193 Overall, there were significant effects of *modality* ($F(2,1402) = 42.83$, $P < .001$, $\eta_p^2 = 0.058$;
194 olfactory < gustatory < trigeminal; all $P < .001$), *time* ($F(2,1402) = 118.47$, $P < .001$, $\eta_p^2 = 0.145$;
195 during < after < before; all $P < .001$), and *gender* ($F(1,701) = 5.52$, $P = 0.019$, $\eta_p^2 = 0.008$; women < men)
196 and significant interactions between these factors (*modality*time*, *modality*time*gender*; all
197 $P < .001$) on chemosensory self-evaluation. To disentangle these interactions, we analyzed data
198 separately per chemosensory modality and time points.

199

200 Chemosensory modality: With regards to olfactory function, significant main effects of *time*
201 ($F(2,1402) = 165.07$, $P < .001$, $\eta_p^2 = 0.191$; during < after < before; all $P < .001$; Figure 3A), *age*
202 ($F(1,701) = 4.42$, $P = .012$, $\eta_p^2 = 0.009$) and *gender* ($F(1,701) = 4.42$, $P = .036$, $\eta_p^2 = 0.006$; women <
203 men) were revealed. In addition, we observed significant interactions of *time*age*
204 ($F(2,1402) = 23.39$, $P < .001$, $\eta_p^2 = 0.032$) and *time*gender* ($F(2, 1402) = 21.69$, $P < 0.001$, $\eta_p^2 = 0.030$).

205 With regards to gustatory function, we observed significant main effects of *time*
206 ($F(2,1402) = 102.97$, $P < .001$, $\eta_p^2 = 0.128$; during < after < before; all $P < .001$; Figure 3B) and *gender*
207 ($F(1, 701) = 9.80$, $P = .002$, $\eta_p^2 = 0.014$; women < men), but no effect of *age*. We also observed
208 significant interactions of *time*age* ($F(2, 1402) = 5.97$, $P = .005$, $\eta_p^2 = 0.008$) and *time*gender* ($F(2,$
209 $1402) = 20.02$, $P < .001$, $\eta_p^2 = 0.028$).

210 With regards to trigeminal function, we observed significant main effects of *time*
211 ($F(2,1402)=3.91, P=.020, \eta_p^2=0.006$; during<after<before; all $P<.001$; Figure 3C), and age
212 ($(1,701)=5.08, P=.025, \eta_p^2=0.007$) but no effect of *gender*. We also identified significant
213 interactions of *time*age* ($F(2, 1402)=4.70, P=.016, \eta_p^2=0.007$) and *time*gender* ($F(2,$
214 $1402)=4.50, P=.019, \eta_p^2=0.006$).

215
216 Time point: With regards to chemosensory function before infection, we observed a significant
217 effect of *gender* ($F(1,701)=8.52, P=.004, \eta_p^2=0.012$; men < women), but not of *modality*, *age* nor
218 interactions. During COVID-19, we observed a significant effects of *modality* ($F(2,$
219 $1402)=96.714, P<.001, \eta_p^2=0.121$; olfaction<gustation<trigeminal; all $P<.001$), *gender* ($F(1,$
220 $701)=21.98, P<.001, \eta_p^2=0.030$; women<men), and age ($F(1, 701)=4.74, P=.030, \eta_p^2=0.007$).
221 Further, we found significant interactions *modality*age* ($F(2, 1402)=24.185, P<.001, \eta_p^2=0.033$)
222 and *modality*gender* ($F(2, 1402)=6.76, P=.002, \eta_p^2=0.010$). Finally, after infection, we observed
223 a significant effect of *modality* ($F(2, 1402)=9.91, P<.001, \eta_p^2=0.014$;
224 olfaction<gustation<trigeminal; all $P<.015$), but not of *gender* or *age*, nor any interaction.

225 Compared to baseline (before infection), changes in chemosensory function were
226 correlated for all modalities during infection (olfaction-gustation: $\rho=0.69$; gustation-trigeminal:
227 $\rho=0.43$; olfaction-trigeminal: $\rho=0.33$; all $P<.001$, Figure 4 A-C) and after infection (olfaction-
228 gustation: $\rho=0.69$; gustation-trigeminal: $\rho=0.40$; olfaction-trigeminal: $\rho=0.36$; all $P<.001$, Figure
229 4 D-F).

230

231 **Qualitative disorders:**

232 Among included participants, 78 (11.1%) reported parosmia, 73 (10.4%) experienced
233 phantosmia and/or 82 (11.6%) had waxing and waning of olfaction following infection. In
234 addition, 42 (6.0%) claimed that they experienced other forms of OD (hyposmia to specific
235 substances, hyperosmia, parosmia only at high concentrations or slow identification times).
236 Furthermore, 335 (47.6%) participants reported changes to perception of sweet, 338 (48.0%)
237 salty, 293 (41.6%) sour, 309 (43.9%) bitter and 281 (39.9%) umami. A total of 275 (39.1%)
238 participants reported alterations in all 5 tastes.

239

240 **Chemosensory Perception Test:**

241 Among the 704 participants, 137 (19.5%) had a CPT score suggestive of OD. Mean CPT scores
242 were lower for olfaction than gustation (7.84 (1.78) vs 8.42 (2.31); $Z=8.193$, $P<.001$). Neither
243 *age* nor *gender* had an effect on CPT scores. CPT scores correlated with self-reported
244 chemosensory abilities at testing time (olfaction: $\rho=0.67$; gustation: $\rho=0.51$; $P<.001$ for both).

245 **Discussion:**

246 This study reports chemosensory dysfunction 3 to 7 months following SARS-CoV-2 infection in
247 a large cohort of RT-PCR-confirmed healthcare workers. In addition to confirming the now well-
248 established detrimental effect of acute COVID-19 on all three chemosensory systems (olfactory,
249 gustatory, trigeminal), our major findings are: (1) the detrimental effect of COVID-19 lasts
250 beyond the acute phase after the infection, half of those affected indicated that olfactory function
251 had not returned to the baseline levels 3 to 7 months later, while 20% of infected participants
252 reported scores in a formal test that are consistent with the presentation of hyposmia/anosmia; (2)
253 approximately 10% of the patients exhibit parosmia and/or phantosmia; (3) women are more
254 heavily affected than men.

255 We observed chemosensory dysfunction in the acute phase of COVID-19, which was
256 most pronounced for olfactory function, but less so for gustatory function and even less for
257 trigeminal function. The proportion of participants describing OD and GD in the acute phase of
258 COVID-19 in this study was comparable to earlier studies (Hajikhani, Calcagno et al. 2020).
259 Although the proportions of participants indicating a decrease in olfaction or gustation were
260 comparable, the olfactory system seems to be more severely impaired. Given the cross-sectional
261 design of the present study, recall bias may have a role to play in the prevalence of OD and GD
262 in similar study populations, but published studies with little to no recall bias also report
263 equivalent prevalence of OD and GD (Andrews, Pendolino et al. 2020, Lechien, Chiesa-Estomba
264 et al. 2020, Petrocelli, Cutrupi et al. 2021). Longitudinal studies are needed to further assess the
265 relationship between OD and GD in COVID-19. Nevertheless, on average 4.8 months after
266 infection and thus well after the acute phase, approximately 50% and 40% of patients reported
267 persistent alterations in olfactory and gustatory function, respectively; these numbers are higher

268 than what has been reported in some studies (Boscolo-Rizzo, Guida et al. 2021, Capelli and Gatti
269 2021, Lechien, Chiesa-Estomba et al. 2021) and lower than reported by others (Hopkins, Surda
270 et al. 2021). The great variability in these results is due to very different study designs (self-
271 report vs. psychophysical test; prospective vs cross-sectional) and studied populations (of
272 different ethnicity and under different effects of selection bias), which either influence the
273 measure of OD and GD in study populations or directly impact the baseline prevalence of OD
274 and GD during COVID-19, offsetting all prevalence calculated at further points (Mazzatenta,
275 Neri et al. 2020, von Bartheld, Hagen et al. 2020). For instance, in the study population included
276 in this study, prevalence of OD decreases to 18.9% of participants when measured using the CPT
277 at 4.8 (SD: 0.8) months after infection. The difference in these frequencies could be due to a
278 higher sensitivity of the self-reported alterations compared to the CPT. Participants with milder
279 forms of persistent hyposmia or with higher baseline olfactory sensitivity may have higher scores
280 on the semi-objective CPT yet have not recovered entirely. We found a moderate-to-strong
281 correlation between self-reported olfactory and gustatory changes, which were stronger than with
282 self-reported trigeminal changes. This could be due to similar pathophysiological alterations in
283 the olfactory and gustatory systems and their differences from that of the trigeminal system.

284 Knowing that the general population often mixes up retro-olfaction (perceiving odors
285 from the substances in the mouth traveling posteriorly and rostrally to the olfactory epithelium)
286 with taste, an alternative explanation would be a misunderstanding of this nuance by participants
287 despite the fact that specific definitions for each modality were given (Landis, Frasnelli et al.
288 2005)(Malaty and Malaty 2013). The latter hypothesis is more probable since the correlation
289 between gustatory self-report and CPT gustatory scores using strict gustatory stimuli (salt, sugar)
290 is lower than the correlation between olfactory self-report and CPT olfactory scores. When

291 tasting strictly gustatory stimuli in the CPT, participants reflect solely on their sense of taste,
292 without the influence of retronasal sensations. These tests have the potential to be more accurate
293 than simple subjective measures and could simplify large-scale psychophysical chemosensory
294 testing. Others have reported the usefulness of similar self-administered chemosensory tests in
295 the detection and follow-up of COVID-19-induced chemosensory dysfunctions (*Vaira, Salzano*
296 *et al. 2020, Petrocelli, Cutrupi et al. 2021*). Different theories have been proposed to explain the
297 persistence of OD in certain individuals, ranging from olfactory epithelium dysfunction to
298 central nervous system infection (Bilinska and Butowt 2020, Butowt and von Bartheld 2020,
299 Solomon 2021). Since cells of the olfactory epithelium possess the ability to regenerate, the re-
300 establishment of olfactory function is possible in the context of postinfectious OD (Cavazzana,
301 Larsson et al. 2018), as well as in COVID-19-related OD, where 75-85% of the affected
302 individuals recovered olfactory function within 60 days (Mullol, Alobid et al. 2020, Lechien,
303 Chiesa-Estomba et al. 2021). The exact rate of olfactory recovery is still unknown, while post-
304 COVID-19 OD prevalence ranging from 11%-60% at 6 months according to a recent study
305 (Xydakis, Albers et al.). In addition to OD and GD, TD has also been reported in patients with
306 COVID-19 (Cooper, Brann et al. 2020, Parma, Ohla et al. 2020).

307 Persistent chemosensory dysfunctions may be a sign of chronic central nervous system
308 alterations (Gori, Leone et al. 2020, Wu, Xu et al. 2020), and there is now evidence that SARS-
309 CoV-2 can infect olfactory sensory neurons in humans (Meinhardt, Radke et al. 2020, de Melo,
310 Lazarini et al. 2021). Other viruses, such as the Japanese encephalitis virus, Varicella-Zoster
311 virus, measles virus, human immunodeficiency virus and CoVs, were shown to invade the CNS
312 (Koyuncu, Hogue et al. 2013). Febrile seizures, loss of consciousness, convulsions, ataxia, status
313 epilepticus, encephalitis, myelitis, neuritis and extrapyramidal symptoms are among extra-

314 pulmonary symptoms that have been described (Bohmwald, Gálvez et al. 2018). However, no
315 evidence of intra-parenchymal replication has been found yet. Additional findings include the
316 presence of local immune processes (Saussez, Sharma et al. 2021) and persistence of viral
317 fragments in the olfactory epithelium (de Melo, Lazarini et al. 2021). Therefore, chronic post-
318 COVID-19 inflammation in the olfactory pathway (epithelium, bulb) with or without direct
319 infection is the most probable pathophysiological explanation of post-COVID-19 OD
320 (Kirschenbaum, Imbach et al. 2020, Vaira, Hopkins et al. 2020, Xydakis, Albers et al.). The
321 persistence of postinfectious neurological inflammation may contribute to the development or
322 aggravation of chronic neurological diseases such as Parkinson, multiple sclerosis, or psychiatric
323 outcomes (Morris 1985, Johnson-Lussenburg and Zheng 1987, Fazzini, Fleming et al. 1992,
324 Murray, Brown et al. 1992, Stewart, Mounir et al. 1992, Cristallo, Gambaro et al. 1997, Arbour,
325 Day et al. 2000, Koyuncu, Hogue et al. 2013, Cohen, Eichel et al. 2020, Taquet, Geddes et al.
326 2021). These patients should be followed up to document the development of neurological
327 sequelae.

328 Moreover, approximately 10% reported parosmia and/or phantosmia following SARS-
329 CoV-2 infection. These qualitative smell disorders usually involve unpleasant olfactory
330 sensations (rotten eggs, sewage, smoke). While the exact patho-mechanism of parosmia and
331 phantosmia are still to be elucidated, parosmia is probably linked to altered peripheral
332 input/central processing of olfactory stimuli (Iannilli, Leopold et al. 2019). Importantly, patients
333 with postviral OD and parosmia exhibit better recovery rates following olfactory training than
334 those without parosmia (Liu, Sabha et al. 2021). Follow-ups will determine to what extent
335 parosmia predicts a better outcome.

336 Women's chemical senses were more affected than men during and after COVID-19
337 infection. Women typically have better scores in olfactory testing than men at baseline (Wang,
338 Zhang et al. 2019). However, in line with our results, studies have revealed that women exhibit a
339 higher prevalence and a longer persistence of postviral OD (Liu, Pinto et al. 2016, Sorokowski,
340 Karwowski et al. 2019). Gender differences could be explained by a multitude of
341 neuroendocrine, social, and cognitive factors (Sorokowski, Karwowski et al. 2019). We also
342 found that older individuals have lower olfactory and gustatory sensitivities, especially during
343 the acute phase of COVID-19.

344 Currently, there is no approved therapy specifically for COVID-19-induced OD, although
345 experts agree that olfactory training could be prescribed for COVID-induced OD as it has a
346 significant effect on olfactory function according to studies on other viral infections (Damm,
347 Pikart et al. 2014, Sorokowska, Drechsler et al. 2017, Doty 2019, Huart, Philpott et al. 2021).
348 Additionally, oral steroids, intranasal steroids and/or omega-3 supplements may be prescribed on
349 an individual basis (Hopkins, Alanin et al. 2021). Most importantly, long-term follow-up of these
350 patients will be necessary to assess other signs of neurological damage or spontaneous recovery,
351 as recoveries can be possible after a year in other post-viral OD (Lee, Lee et al. 2014).

352

353 Limitations

354 Given the cross-sectional design of the study, a recall bias is possible for all self-reported
355 peri-SARS-CoV-2 infection values before or during the SARS-CoV-2 infection due to the 3-to-
356 7-month gap. This study did not control for potential confounding factors like race and level of
357 education. Finally, the CPT requires further validation for its gustatory and trigeminal
358 components, and it relies on substances found in participants' homes, which may lead to

359 variation in test results due to the differences in the brand, quality, or expiration date of
360 substances and consequently, their ability to trigger equal sensorineural responses.

361 **Conclusions:**

362 Nearly two thirds of SARS-CoV-2 infected patients had chemosensory impairments during their
363 infection and despite improvements, impairments persist in half of them 3 to 7 months after
364 COVID-19. Quantitative and qualitative olfactory dysfunction as well as persisting gustatory and
365 trigeminal deficits were common in the cohort presented in this study. Given the frequency of
366 these problems and the possible neurological underpinnings of these observations, it will be
367 critical to understand the underlying mechanisms of these chemosensory dysfunctions, their
368 evolution, and possible therapeutic options.

369 **Acknowledgments:**

370 We thank Josiane Rivard for preparing the online questionnaire, Cécilia Tremblay, Émilie
371 Aubry-Lafontaine and Frédérique Roy-Côté for data collection and the validation of the
372 Chemosensory Perception Test, and all study participants and frontline healthcare workers facing
373 the COVID-19 pandemic. This work was supported by Fonds de recherche du Québec – Santé
374 (chercheur boursier junior 2 #283144 to JF). NB and JF had full access to all the data in the study
375 and take responsibility for the integrity of the data and the accuracy of the data analysis. FGL is
376 the recipient of a tier-2 Canada research Chair. All authors declare no conflict of interest.

377 **References:**

- 378 Allen, M., D. Poggiali, K. Whitaker, T. Marshall, J. van Langen and R. Kievit (2021). "Raincloud plots: a
379 multi-platform tool for robust data visualization [version 2; peer review: 2 approved]." Wellcome Open
380 Research **4**(63).
- 381 Andrews, P. J., A. L. Pendolino, G. Ottaviano, B. Scarpa, J. Grant, P. Gaudio, A. Bordin, R. Marchese-
382 Ragona, D. Leoni, A. Cattelan, A. Kaura, S. Gane, N. J. Hamilton, D. Choi and J. A. Andrews (2020).
383 "Olfactory and taste dysfunction among mild-to-moderate symptomatic COVID-19 positive health care
384 workers: An international survey." Laryngoscope investigative otolaryngology **5**(6): 1019-1028.
- 385 Arbour, N., R. Day, J. Newcombe and P. J. Talbot (2000). "Neuroinvasion by human respiratory
386 coronaviruses." J Virol **74**(19): 8913-8921.
- 387 Aschenbrenner, K., C. Hummel, K. Teszmer, F. Krone, T. Ishimaru, H. S. Seo and T. Hummel (2008). "The
388 influence of olfactory loss on dietary behaviors." Laryngoscope **118**(1): 135-144.
- 389 Bilinska, K. and R. Butowt (2020). "Anosmia in COVID-19: A Bumpy Road to Establishing a Cellular
390 Mechanism." ACS Chem Neurosci.
- 391 Bohmwald, K., N. M. S. Gálvez, M. Ríos and A. M. Kalergis (2018). "Neurologic Alterations Due to
392 Respiratory Virus Infections." Front Cell Neurosci **12**: 386.
- 393 Boscolo-Rizzo, P., F. Guida, J. Polesel, A. V. Marcuzzo, P. Antonucci, V. Capriotti, E. Sacchet, F. Cragolini,
394 A. D'Alessandro, E. Zanelli, R. Marzolino, C. Lazzarin, M. Tofanelli, N. Gardenal, D. Borsetto, C. Hopkins, L.
395 A. Vaira and G. Tirelli (2021). "Self-reported smell and taste recovery in coronavirus disease 2019
396 patients: a one-year prospective study." European archives of oto-rhino-laryngology : official journal of
397 the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German
398 Society for Oto-Rhino-Laryngology - Head and Neck Surgery: 1-6.
- 399 Butowt, R. and C. S. von Bartheld (2020). "Anosmia in COVID-19: Underlying Mechanisms and
400 Assessment of an Olfactory Route to Brain Infection." Neuroscientist.
- 401 Capelli, M. and P. Gatti (2021). "Anosmia in the first coronavirus disease 2019 outbreak in Europe:
402 functional recovery after eight months." The Journal of laryngology and otology: 1-5.
- 403 Carazo, S. L. D., Villeneuve J, Martin R, Deshaies P, Denis G, , Adib G, Tissot F, Dionne M, De Serres G
404 (2021). "Characterization and evolution of infection control practices among SARS-CoV-2 infected
405 healthcare workers of acute care hospitals and long-term care facilities in Quebec, Canada, Spring
406 2020." Infect Contr Hospit Epidemiol.
- 407 Cavazzana, A., M. Larsson, M. Münch, A. Hähner and T. Hummel (2018). "Postinfectious olfactory loss: A
408 retrospective study on 791 patients." Laryngoscope **128**(1): 10-15.
- 409 Cohen, M. E., R. Eichel, B. Steiner-Birmanns, A. Janah, M. Ioshpa, R. Bar-Shalom, J. J. Paul, H. Gaber, V.
410 Skrahina, N. M. Bornstein and G. Yahalom (2020). "A case of probable Parkinson's disease after SARS-
411 CoV-2 infection." Lancet Neurol **19**(10): 804-805.
- 412 Cooper, K. W., D. H. Brann, M. C. Farruggia, S. Bhutani, R. Pellegrino, T. Tsukahara, C. Weinreb, P. V.
413 Joseph, E. D. Larson, V. Parma, M. W. Albers, L. A. Barlow, S. R. Datta and A. Di Pizio (2020). "COVID-19
414 and the Chemical Senses: Supporting Players Take Center Stage." Neuron **107**(2): 219-233.
- 415 Cristallo, A., F. Gambaro, G. Biamonti, P. Ferrante, M. Battaglia and P. M. Cereda (1997). "Human
416 coronavirus polyadenylated RNA sequences in cerebrospinal fluid from multiple sclerosis patients." New
417 Microbiol **20**(2): 105-114.
- 418 Croy, I., S. Nordin and T. Hummel (2014). "Olfactory Disorders and Quality of Life—An Updated Review."
419 Chemical Senses **39**(3): 185-194.
- 420 Damm, M., L. K. Pikart, H. Reimann, S. Burkert, Ö. Göktas, B. Haxel, S. Frey, I. Charalampakis, A. Beule, B.
421 Renner, T. Hummel and K. B. Hüttenbrink (2014). "Olfactory training is helpful in postinfectious olfactory
422 loss: a randomized, controlled, multicenter study." Laryngoscope **124**(4): 826-831.

423 de Melo, G. D., F. Lazarini, S. Levallois, C. Hautefort, V. Michel, F. Larrous, B. Verillaud, C. Aparicio, S.
424 Wagner, G. Gheusi, L. Kergoat, E. Kornobis, F. Donati, T. Cokelaer, R. Hervochon, Y. Madec, E. Roze, D.
425 Salmon, H. Bourhy, M. Lecuit and P.-M. Lledo (2021). "COVID-19–related anosmia is associated with viral
426 persistence and inflammation in human olfactory epithelium and brain infection in hamsters." Science
427 Translational Medicine **13**(596): eabf8396.
428 Doty, R. L. (2019). "Treatments for smell and taste disorders: A critical review." Handb Clin Neurol **164**:
429 455-479.
430 Doty, R. L., P. Shaman, C. P. Kimmelman and M. S. Dann (1984). "University of Pennsylvania Smell
431 Identification Test: a rapid quantitative olfactory function test for the clinic." Laryngoscope **94**(2 Pt 1):
432 176-178.
433 Doty, R. L., C. Wylie and M. Potter (2021). "Validation of the Waterless Empirical Taste Test
434 (WETT<sup>®</sup>)." Behavior research methods **53**(2): 864-873.
435 Fazzini, E., J. Fleming and S. Fahn (1992). "Cerebrospinal fluid antibodies to coronavirus in patients with
436 Parkinson's disease." Mov Disord **7**(2): 153-158.
437 Gerkin, R., K. Ohla, M. Veldhuizen, P. Joseph, C. Kelly, A. Bakke, K. Steele, M. Farruggia, R. Pellegrino, M.
438 Pepino, C. Bouysset, G. Soler, V. Pereda-Loth, M. Dibattista, K. Cooper, I. Croijmans, A. Di Pizio, M.
439 Ozdener, A. Fjaeldstad and V. Parma (2021). "Recent Smell Loss Is the Best Predictor of COVID-19 Among
440 Individuals With Recent Respiratory Symptoms." Chemical Senses **46**.
441 Gonzales, G. M. and M. J. Cook (2007). CHAPTER 13 - DISORDERS OF SMELL AND TASTE. Neurology and
442 Clinical Neuroscience. A. H. V. Schapira, E. Byrne, S. DiMauro et al. Philadelphia, Mosby: 171-177.
443 Gori, A., F. Leone, L. Loffredo, B. L. Cinicola, G. Brindisi, G. De Castro, A. Spalice, M. Duse and A. M. Zicari
444 (2020). "COVID-19-Related Anosmia: The Olfactory Pathway Hypothesis and Early Intervention." Frontiers in neurology **11**: 956-956.
445 Hajikhani, B., T. Calcagno, M. J. Nasiri, P. Jamshidi, M. Dadashi, M. Goudarzi, A. A. Eshraghi and M.
446 Mirsaedi (2020). "Olfactory and gustatory dysfunction in COVID-19 patients: A meta-analysis study." Physiol Rep **8**(18): e14578.
447 Havervall, S., A. Rosell, M. Phillipson, S. M. Mangsbo, P. Nilsson, S. Hober and C. Thålin (2021).
448 "Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care
449 Workers." JAMA **325**(19): 2015-2016.
450 Hintschich, C. A., J. J. Wenzel, T. Hummel, M. K. Hankir, T. Kühnel, V. Vielsmeier and C. Bohr (2020).
451 "Psychophysical tests reveal impaired olfaction but preserved gustation in COVID-19 patients." International forum of allergy & rhinology **10**(9): 1105-1107.
452 Hopkins, C., M. Alanin, C. Philpott, P. Harries, K. Whitcroft, A. Qureishi, S. Anari, Y. Ramakrishnan, A.
453 Sama, E. Davies, B. Stew, S. Gane, S. Carrie, I. Hathorn, R. Bhalla, C. Kelly, N. Hill, D. Boak and B. Nirmal
454 Kumar (2021). "Management of new onset loss of sense of smell during the COVID-19 pandemic - BRS
455 Consensus Guidelines." Clin Otolaryngol **46**(1): 16-22.
456 Hopkins, C., P. Surda, L. A. Vaira, J. R. Lechien, M. Safarian, S. Saussez and N. Kumar (2021). "Six month
457 follow-up of self-reported loss of smell during the COVID-19 pandemic." Rhinology **59**(1): 26-31.
458 Hopkins, C., P. Surda, E. Whitehead and B. N. Kumar (2020). "Early recovery following new onset
459 anosmia during the COVID-19 pandemic – an observational cohort study." Journal of Otolaryngology -
460 Head & Neck Surgery **49**(1): 26.
461 Huart, C., C. M. Philpott, A. Altundag, A. W. Fjaeldstad, J. Frasnelli, S. Gane, J. W. Hsieh, E. H. Holbrook, I.
462 Konstantinidis, B. N. Landis, A. Macchi, C. A. Mueller, S. Negoias, J. M. Pinto, S. C. Poletti, V. R.
463 Ramakrishnan, P. Rombaux, J. Vodicka, A. Welge-Lüessen, K. L. Whitcroft and T. Hummel (2021).
464 "Systemic corticosteroids in coronavirus disease 2019 (COVID-19)-related smell dysfunction: an
465 international view." International forum of allergy & rhinology **11**(7): 1041-1046.
466 Hummel, T., K. L. Whitcroft, P. Andrews, A. Altundag, C. Cinghi, R. M. Costanzo, M. Damm, J. Frasnelli, H.
467 Gudziol, N. Gupta, A. Haehner, E. Holbrook, S. C. Hong, D. Hornung, K. B. Hüttenbrink, R. Kamel, M.

471 Kobayashi, I. Konstantinidis, B. N. Landis, D. A. Leopold, A. Macchi, T. Miwa, R. Moesges, J. Mullol, C. A.
472 Mueller, G. Ottaviano, G. C. Passali, C. Philpott, J. M. Pinto, V. J. Ramakrishnan, P. Rombaux, Y. Roth, R.
473 A. Schlosser, B. Shu, G. Soler, P. Stjärne, B. A. Stuck, J. Vodicka and A. Welge-Luessen (2016). "Position
474 paper on olfactory dysfunction." *Rhinology* **56**(1): 1-30.
475 Iannilli, E., D. A. Leopold, D. E. Hornung and T. Hummel (2019). "Advances in Understanding Parosmia:
476 An fMRI Study." *ORL J Otorhinolaryngol Relat Spec* **81**(4): 185-192.
477 Johnson-Lussenburg, C. M. and Q. Zheng (1987). "Coronavirus and multiple sclerosis: results of a
478 case/control longitudinal serological study." *Adv Exp Med Biol* **218**: 421-429.
479 Kelly, M. (2012). "Scent of a patient: an underestimated role in clinical practice?" *The British journal of*
480 *general practice : the journal of the Royal College of General Practitioners* **62**(600): 378-378.
481 Kirschenbaum, D., L. L. Imbach, S. Ulrich, E. J. Rushing, E. Keller, R. R. Reimann, K. B. M. Frauenknecht,
482 M. Lichtblau, M. Witt, T. Hummel, P. Steiger, A. Aguzzi and K. Frontzek (2020). "Inflammatory olfactory
483 neuropathy in two patients with COVID-19." *The Lancet* **396**(10245): 166.
484 Kohli, P., Z. M. Soler, S. A. Nguyen, J. S. Muus and R. J. Schlosser (2016). "The Association Between
485 Olfaction and Depression: A Systematic Review." *Chem Senses* **41**(6): 479-486.
486 Koyuncu, O. O., I. B. Hogue and L. W. Enquist (2013). "Virus infections in the nervous system." *Cell Host*
487 *Microbe* **13**(4): 379-393.
488 Landis, B. N., J. Frasnelli, I. Croy and T. Hummel (2010). "Evaluating the clinical usefulness of structured
489 questions in parosmia assessment." *Laryngoscope* **120**(8): 1707-1713.
490 Landis, B. N., J. Frasnelli, J. Reden, J. S. Lacroix and T. Hummel (2005). "Differences Between Orthonasal
491 and Retronasal Olfactory Functions in Patients With Loss of the Sense of Smell." *Archives of*
492 *Otolaryngology–Head & Neck Surgery* **131**(11): 977-981.
493 Landis, B. N., T. Hummel, M. Hugentobler, R. Giger and J. S. Lacroix (2003). "Ratings of overall olfactory
494 function." *Chem Senses* **28**(8): 691-694.
495 Landis, B. N., C. G. Konnerth and T. Hummel (2004). "A study on the frequency of olfactory dysfunction."
496 *Laryngoscope* **114**(10): 1764-1769.
497 Le Bon, S.-D., N. Pisarski, J. Verbeke, L. Prunier, G. Cavelier, M.-P. Thill, A. Rodriguez, D. Dequanter, J. R.
498 Lechien, O. Le Bon, T. Hummel and M. Horoi (2020). "Psychophysical evaluation of chemosensory
499 functions 5 weeks after olfactory loss due to COVID-19: a prospective cohort study on 72 patients." *Eur*
500 *Arch Otorhinolaryngol*.
501 Lechien, J. R., C. M. Chiesa-Estomba, E. Beckers, V. Mustin, M. Ducarme, F. Journe, A. Marchant, L.
502 Jouffe, M. R. Barillari, G. Cammaroto, M. P. Ciciu, S. Hans and S. Saussez (2021). "Prevalence and 6-
503 month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients." *Journal of*
504 *Internal Medicine* **n/a**(n/a).
505 Lechien, J. R., C. M. Chiesa-Estomba, E. Beckers, V. Mustin, M. Ducarme, F. Journe, A. Marchant, L.
506 Jouffe, M. R. Barillari, G. Cammaroto, M. P. Ciciu, S. Hans and S. Saussez (2021). "Prevalence and 6-
507 month recovery of olfactory dysfunction: a multicentre study of 1363 COVID-19 patients." *Journal of*
508 *Internal Medicine* **290**(2): 451-461.
509 Lechien, J. R., C. M. Chiesa-Estomba, D. R. De Siati, M. Horoi, S. D. Le Bon, A. Rodriguez, D. Dequanter, S.
510 Blecic, F. El Afia, L. Distinguin, Y. Chekkoury-Idrissi, S. Hans, I. L. Delgado, C. Calvo-Henriquez, P. Lavigne,
511 C. Falanga, M. R. Barillari, G. Cammaroto, M. Khalife, P. Leich, C. Souchay, C. Rossi, F. Journe, J. Hsieh, M.
512 Edjlali, R. Carlier, L. Ris, A. Lovato, C. De Filippis, F. Coppee, N. Fakhry, T. Ayad and S. Saussez (2020).
513 "Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the
514 coronavirus disease (COVID-19): a multicenter European study." *Eur Arch Otorhinolaryngol*.
515 Lee, D., W. Lee, J. Wee and J.-W. Kim (2014). "Prognosis of postviral olfactory loss: Follow-up study for
516 longer than one year." *American Journal of Rhinology & Allergy* **28**.
517 Liu, D. T., M. Sabha, M. Damm, C. Philpott, A. Oleszkiewicz, A. Hähner and T. Hummel (2021). "Parosmia
518 is Associated with Relevant Olfactory Recovery After Olfactory Training." *Laryngoscope* **131**(3): 618-623.

519 Liu, J., J. M. Pinto, L. Yang, L. Li, J. Sun, X. Miao, K. Li, G. Chen and Y. Wei (2016). "Gender difference in
520 Chinese adults with post-viral olfactory disorder: a hospital-based study." *Acta Otolaryngol* **136**(9): 976-
521 981.

522 Lötsch, J. and T. Hummel (2019). "Clinical Usefulness of Self-Rated Olfactory Performance-A Data
523 Science-Based Assessment of 6000 Patients." *Chem Senses* **44**(6): 357-364.

524 Malaty, J. and I. A. Malaty (2013). "Smell and taste disorders in primary care." *Am Fam Physician* **88**(12):
525 852-859.

526 Mattes, R., B. Cowart, M. Schiavo, C. Arnold, B. Garrison, M. Kare and L. Lowry (1990). "Dietary
527 evaluation of patients with smell and/or taste disorders." *The American journal of clinical nutrition* **51**:
528 233-240.

529 Mazzatenta, A., G. Neri, D. D'Ardes, C. De Luca, S. Marinari, E. Porreca, F. Cipollone, J. Vecchiet, C.
530 Falcicchia, V. Panichi, N. Origlia and C. Di Giulio (2020). "Smell and Taste in Severe CoVID-19: Self-
531 Reported vs. Testing." *Frontiers in medicine* **7**: 589409-589409.

532 Meinhardt, J., J. Radke, C. Dittmayer, J. Franz, C. Thomas, R. Mothes, M. Laue, J. Schneider, S. Brünink, S.
533 Greuel, M. Lehmann, O. Hassan, T. Aschman, E. Schumann, R. L. Chua, C. Conrad, R. Eils, W. Stenzel, M.
534 Windgassen, L. Rößler, H. H. Goebel, H. R. Gelderblom, H. Martin, A. Nitsche, W. J. Schulz-Schaeffer, S.
535 Hakrrouch, M. S. Winkler, B. Tampe, F. Scheibe, P. Körtvélyessy, D. Reinhold, B. Siegmund, A. A. Kühl, S.
536 Elezkurtaj, D. Horst, L. Oesterhelweg, M. Tsokos, B. Ingold-Heppner, C. Stadelmann, C. Drost, V. M.
537 Corman, H. Radbruch and F. L. Heppner (2020). "Olfactory transmucosal SARS-CoV-2 invasion as a port
538 of central nervous system entry in individuals with COVID-19." *Nat Neurosci*.

539 Moein, S. T., S. M. Hashemian, B. Mansourafshar, A. Khorram-Tousi, P. Tabarsi and R. L. Doty (2020).
540 "Smell dysfunction: a biomarker for COVID-19." *Int Forum Allergy Rhinol*.

541 Morris, J. A. (1985). "Clinical viral infections and multiple sclerosis." *Lancet* **2**(8449): 273.

542 Mullo, J., I. Alobid, F. Mariño-Sánchez, A. Izquierdo-Domínguez, C. Marin, L. Klimek, D.-Y. Wang and Z.
543 Liu (2020). "The Loss of Smell and Taste in the COVID-19 Outbreak: a Tale of Many Countries." *Current*
544 *allergy and asthma reports* **20**(10): 61-61.

545 Murray, R. S., B. Brown, D. Brian and G. F. Cabirac (1992). "Detection of coronavirus RNA and antigen in
546 multiple sclerosis brain." *Ann Neurol* **31**(5): 525-533.

547 Parma, V., M. E. Hannum, M. O'Leary, R. Pellegrino, N. E. Rawson, D. R. Reed and P. H. Dalton (2021).
548 "SCENTinel 1.0: development of a rapid test to screen for smell loss." *Chem Senses*.

549 Parma, V., K. Ohla, M. G. Veldhuizen, M. Y. Niv, C. E. Kelly, A. J. Bakke, K. W. Cooper, C. Bouysset, N.
550 Pirastu, M. Dibattista, R. Kaur, M. T. Liuzza, M. Y. Pepino, V. Schöpf, V. Pereda-Loth, S. B. Olsson, R. C.
551 Gerkin, P. R. Domínguez, J. Albayay, M. C. Farruggia, S. Bhutani, A. W. Fjaeldstad, R. Kumar, A. Menini,
552 M. Bensafi, M. Sandell, I. Konstantinidis, A. Di Pizio, F. Genovese, L. Öztürk, T. Thomas-Danguin, J.
553 Frasnelli, S. Boesveldt, Ö. Saatci, L. R. Saraiva, C. Lin, J. Golebiowski, L.-D. Hwang, M. H. Ozdener, M. D.
554 Guàrdia, C. Laudamiel, M. Ritchie, J. Havlíček, D. Pierron, E. Roura, M. Navarro, A. A. Nolden, J. Lim, K.
555 Whitcroft, L. R. Colquitt, C. Ferdenzi, E. V. Brindha, A. Altundag, A. Macchi, A. Nunez-Parra, Z. M. Patel, S.
556 Fiorucci, C. M. Philpott, B. C. Smith, J. N. Lundström, C. Mucignat, J. K. Parker, M. van den Brink, M.
557 Schmuker, F. P. S. Fischmeister, T. Heinbockel, V. D. C. Shields, F. Faraji, E. Enrique Santamaría, W. E. A.
558 Fredborg, G. Morini, J. K. Olofsson, M. Jalessi, N. Karni, A. D'Errico, R. Alizadeh, R. Pellegrino, P. Meyer, C.
559 Huart, B. Chen, G. M. Soler, M. K. Alwashahi, O. Abdulrahman, A. Welge-Lüssen, P. Dalton, J. Freiherr, C.
560 H. Yan, J. H. B. de Groot, V. V. Voznessenskaya, H. Klein, J. Chen, M. Okamoto, E. A. Sell, P. B. Singh, J.
561 Walsh-Messinger, N. S. Archer, S. Koyama, V. Deary, S. C. Roberts, H. Yanik, S. Albayrak, L. M. Novákov, I.
562 Croijmans, P. P. Mazal, S. T. Moein, E. Margulis, C. Mignot, S. Mariño, D. Georgiev, P. K. Kaushik, B.
563 Malnic, H. Wang, S. Seyed-Allaei, N. Yoluk, S. Razzaghi, J. M. Justice, D. Restrepo, J. W. Hsieh, D. R. Reed,
564 T. Hummel, S. D. Munger and J. E. Hayes (2020). "More than smell. COVID-19 is associated with severe
565 impairment of smell, taste, and chemesthesis." *medRxiv*: 2020.2005.2004.20090902.

566 Petrocelli, M., S. Cutrupi, G. Salzano, F. Maglitto, F. A. Salzano, J. R. Lechien, S. Saussez, P. Boscolo-Rizzo,
567 G. De Riu and L. A. Vaira (2021). "Six-month smell and taste recovery rates in coronavirus disease 2019
568 patients: a prospective psychophysical study." The Journal of Laryngology & Otology **135**(5): 436-441.
569 Saussez, S., S. Sharma, A. Thiriad, V. Olislagers, I. Vu Duc, S. D. Le Bon, M. Khalife, S. Hans, G. De Riu, C.
570 Hopkins, J. R. Lechien, L. A. Vaira and A. Marchant (2021). "Predictive factors of smell recovery in a
571 clinical series of 288 coronavirus disease 2019 patients with olfactory dysfunction." Eur J Neurol.
572 Schiffman, S. S. (2007). Smell and Taste. Encyclopedia of Gerontology (Second Edition). J. E. Birren. New
573 York, Elsevier: 515-525.
574 Sjölund, S., M. Larsson, J. K. Olofsson, J. Seubert and E. J. Laukka (2017). "Phantom Smells: Prevalence
575 and Correlates in a Population-Based Sample of Older Adults." Chemical senses **42**(4): 309-318.
576 Solomon, T. (2021). "Neurological infection with SARS-CoV-2 — the story so far." Nature Reviews
577 Neurology **17**(2): 65-66.
578 Sorokowska, A., E. Drechsler, M. Karwowski and T. Hummel (2017). "Effects of olfactory training: a meta-
579 analysis." Rhinology **55**(1): 17-26.
580 Sorokowski, P., M. Karwowski, M. Misiak, M. K. Marczak, M. Dziekan, T. Hummel and A. Sorokowska
581 (2019). "Sex Differences in Human Olfaction: A Meta-Analysis." **10**(242).
582 Speth, M. M., T. Singer-Cornelius, M. Oberle, I. Gengler, S. J. Brockmeier and A. R. Sedaghat (2020).
583 "Olfactory Dysfunction and Sinonasal Symptomatology in COVID-19: Prevalence, Severity, Timing, and
584 Associated Characteristics." Otolaryngol Head Neck Surg.
585 Spinato, G., C. Fabbris, J. Polesel, D. Cazzador, D. Borsetto, C. Hopkins and P. Boscolo-Rizzo (2020).
586 "Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection." JAMA
587 **323**(20): 2089-2090.
588 Stewart, J. N., S. Mounir and P. J. Talbot (1992). "Human coronavirus gene expression in the brains of
589 multiple sclerosis patients." Virology **191**(1): 502-505.
590 Taquet, M., J. R. Geddes, M. Husain, S. Luciano and P. J. Harrison (2021). "6-month neurological and
591 psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic
592 health records." Lancet Psychiatry.
593 Vaira, L. A., C. Hopkins, G. Salzano, M. Petrocelli, A. Melis, M. Cucurullo, M. Ferrari, L. Gagliardini, C.
594 Pipolo, G. Deiana, V. Fiore, A. De Vito, N. Turra, S. Canu, A. Maglio, A. Serra, F. Bussu, G. Madeddu, S.
595 Babudieri, A. Giuseppe Fois, P. Pirina, F. A. Salzano, P. De Riu, F. Biglioli and G. De Riu (2020). "Olfactory
596 and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study." Head &
597 Neck **42**(7): 1560-1569.
598 Vaira, L. A., C. Hopkins, A. Sandison, A. Manca, N. Machouchas, D. Turilli, J. R. Lechien, M. R. Barillari, G.
599 Salzano, A. Cossu, S. Saussez and G. De Riu (2020). "Olfactory epithelium histopathological findings in
600 long-term coronavirus disease 2019 related anosmia." The Journal of Laryngology & Otology **134**(12):
601 1123-1127.
602 Vaira, L. A., G. Salzano, M. Petrocelli, G. Deiana, F. A. Salzano and G. De Riu (2020). "Validation of a self-
603 administered olfactory and gustatory test for the remotely evaluation of COVID-19 patients in home
604 quarantine." Head & Neck **42**(7): 1570-1576.
605 von Bartheld, C. S., M. M. Hagen and R. Butowt (2020). "Prevalence of Chemosensory Dysfunction in
606 COVID-19 Patients: A Systematic Review and Meta-analysis Reveals Significant Ethnic Differences." ACS
607 Chem Neurosci **11**(19): 2944-2961.
608 Wang, X., C. Zhang, X. Xia, Y. Yang and C. Zhou (2019). "Effect of gender on odor identification at
609 different life stages: a meta-analysis." Rhinology **57**(5): 322-330.
610 Weiss, J. J., T. Attuquayefio, E. B. White, B. Geng, R. Handoko, R. S. Herz, T. L. White, A. Iwasaki, N. D.
611 Grubaugh, R. Datta, M. Campbell, R. A. Martinello, A. I. Ko, D. M. Small and S. F. Farhadian (2020). "456.
612 Implementing an At-Home Smell Test for Early Assessment of COVID-19 in High-Risk Healthcare
613 Workers." Open Forum Infectious Diseases **7**(Supplement_1): S295-S296.

614 Whitcroft, K. L. and T. Hummel (2020). "Olfactory Dysfunction in COVID-19: Diagnosis and
615 Management." JAMA **323**(24): 2512-2514.

616 Wu, Y., X. Xu, Z. Chen, J. Duan, K. Hashimoto, L. Yang, C. Liu and C. Yang (2020). "Nervous system
617 involvement after infection with COVID-19 and other coronaviruses." Brain, Behavior, and Immunity.

618 Xydakis, M. S., M. W. Albers, E. H. Holbrook, D. M. Lyon, R. Y. Shih, J. A. Frasnelli, A. Pagenstecher, A.
619 Kupke, L. W. Enquist and S. Perlman (2021). "Post-viral effects of COVID-19 in the olfactory system and
620 their implications." The Lancet Neurology.

621 Yang, J. and J. M. Pinto (2016). "The Epidemiology of Olfactory Disorders." Current otorhinolaryngology
622 reports **4**(2): 130-141.

623

624

625 **List of tables:**

626 **Table 1.** COVID-19 symptoms of the 704 participants.

| Symptoms at time of SARS-CoV-2 infection | No. (%) |
|---|----------------|
| Fever | 353 (50.1%) |
| Dry cough | 361 (51.7%) |
| Cough with mucus | 77 (10.9%) |
| Dyspnea | 316 (44.9%) |
| Chest tightness | 201 (28.6%) |
| Runny nose | 226 (32.1%) |
| Sore throat | 330 (46.9%) |
| Changes in food flavor | 471 (66.9%) |
| Changes in smell | 520 (73.9%) |
| Loss of appetite | 323 (45.9%) |
| Headache | 518 (73.6%) |
| Muscle aches | 444 (63.1%) |
| Fatigue | 611 (86.8%) |
| Diarrhea | 259 (36.8%) |
| Abdominal pain | 102 (14.5%) |
| Nausea | 179 (25.4%) |

627

628 **Table 2.** Self-reported chemosensory alterations by age group and gender during and 3 to 7
 629 months following COVID-19 (n=704).


630

| | | During acute COVID-19 | | | 3-7 months after COVID-19 | | |
|----------------------|-----------|-----------------------|-------------------|-------------------|---------------------------|-------------------|-------------------|
| | | Olfaction | Gustation | Trigeminal | Olfaction | Gustation | Trigeminal |
| Age | Gender | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) |
| 18-29 | M (N= 11) | 9 (81.8) | 9 (81.8) | 4 (36.4) | 6 (54.5) | 5 (45.5) | 3 (27.3) |
| | F (N=115) | 106 (92.2) | 106 (92.2) | 54 (47.0) | 68 (59.1) | 55 (47.8) | 16 (13.9) |
| 30-39 | M (N=26) | 23 (88.5) | 21 (80.8) | 12 (46.2) | 13 (50.0) | 7 (26.9) | 4 (15.4) |
| | F (N=153) | 133 (86.9) | 129 (84.3) | 77 (50.3) | 83 (54.2) | 63 (41.2) | 37 (24.2) |
| 40-49 | M (N=33) | 23 (69.7) | 23 (69.7) | 13 (39.4) | 12 (36.4) | 9 (27.3) | 5 (15.2) |
| | F (N=165) | 142 (85.5) | 137 (83.0) | 83 (50.3) | 97 (58.8) | 77 (46.7) | 42 (25.5) |
| 50-59 | M (N=28) | 13 (46.4) | 14 (50.0) | 9 (32.1) | 7 (25.0) | 7 (25.0) | 4 (14.3) |
| | F (N=128) | 100 (78.1) | 102 (79.7) | 66 (51.6) | 62 (48.4) | 57 (44.5) | 39 (30.5) |
| 60+ | M (N=13) | 5 (38.5) | 6 (46.2) | 5 (38.5) | 2 (15.4) | 1 (7.7) | 3 (23.1) |
| | F (N=32) | 19 (59.4) | 27 (84.4) | 15 (46.9) | 16 (50.0) | 14 (43.8) | 11 (34.4) |
| Total (N=704) | | 572 (81.3) | 574 (81.5) | 338 (48.0) | 366 (52.0) | 295 (41.9) | 164 (23.2) |


631 **List of figures:**

632 **Figure 1. Flowchart of participant inclusion/exclusion procedures.** Flowchart of the study

633 design. INSPQ: Institut national de santé publique.




634 **Figure 2. Web-based interface and structure of the online questionnaire.** Left, Self-rating of
 635 olfaction and reporting of CPT using VAS through the web-based interface, as viewed by the
 636 participant. Right, Sections of the online questionnaire. VAS: visual analog scale.




| Consent | |
|---|---|
| Q1-Q4: personal information | <ul style="list-style-type: none"> • Year of birth • Place of residence • Gender |
| Q5-Q10: COVID-related questions | <ul style="list-style-type: none"> • Diagnosis of COVID-19 • Date of symptom onset • Date of positive COVID-19 test • Stage of COVID-19 • COVID-19 related symptoms • Treatment/medication received |
| Q11-Q20: medical history and substance use | <ul style="list-style-type: none"> • Other respiratory diseases in last two weeks • Symptoms associated with respiratory diseases • Treatment received • Usage of cigarette, e-cigarette, marijuana/cannabis • History of other diseases |
| Q21-Q31: self-reported OD, GD and TD scores | <ul style="list-style-type: none"> • Self-evaluation of olfactory, gustatory and trigeminal functions • Change in olfaction and gustation |
| Q32-Q61: Chem sensory Perception Test | <ul style="list-style-type: none"> • Availability of substances at home • Reporting of smell and/or taste of the substance |

637 **Figure 3. Self-reported scores for the chemosensory modalities before, during and after**
638 **COVID-19 infection (n=704).** Raincloud plot representing self-reported scores for olfaction,
639 gustation, and trigeminal function before, during and after COVID-19. Ratings from individual
640 participants are displayed as dots. Boxplots show the first to third quartiles, horizontal line denotes
641 the median, and whiskers denote 1.5 times interquartile range. Compared to baseline, self-reported
642 scores of olfaction, gustation and trigeminal function were significantly lower during COVID-19
643 and have not fully returned to baseline values 5 months after COVID-19.



644 **Figure 4. Correlations between alterations in chemosensory modalities (n=704).** Red squares,
645 correlations between alterations in olfaction, gustation, and trigeminal functions during COVID-
646 19. Grey hexagons, correlations between alterations in olfaction, gustation, and trigeminal
647 functions after COVID-19. Darker colors indicate higher occurrence.
648
649



650 **Supplementary 1:**

651

652 **Validation of the Chemosensory Perception Test**

653 This study was reviewed and approved by the research ethics board of the Université du Québec à
654 Trois-Rivières (CER-20-268-08-01.04). All participants provided a verbal or written informed
655 consent prior to participation.

656 **Experiment 1:**

657 Methods

658 Participants were recruited among previously tested groups. Olfactory testing was performed
659 using the standardized Sniffin' Sticks test at our laboratory from 2016 to 2019. Exclusion criteria
660 was any perceived changes of their sense of smell since previous testing. Participants were
661 distributed into 2 groups based on their Threshold-Discrimination-Identification (TDI) scores.
662 The first group consists of participants with normal olfactory function (normosmia), defined as
663 TDI scores above 30.5⁶¹. The second group had subjective olfactory dysfunction and equivalent
664 TDI scores. Participants were administered CPT by means of a telephone interview.

665 Results:

666 TDI scores in the first group range from 32.5 to 41.5 (N= 19, 9 women and 10 men, age range [60-
667 78]). TDI scores in the second group ranged from 8 to 30.25 (N= 17, 7 women and 10 men, age
668 range [57-77]). CPT scores were positively correlated with the Sniffin' Sticks ($\rho=0.837$, $P<0.001$).
669 A cut-off score of 6 at the CPT had a sensitivity of 0.765 and specificity of 0.895.

670 **Experiment 2:**

671 Methods:

672 Participants were recruited among previously tested groups, participants from this cross-sectional
673 study and in the public via social media. They were administered the University of Pennsylvania

674 Smell Identification Test (UPSIT) (which was sent by mail) and the CPT under direct supervision
675 through videoconferencing. Participants were distributed into 2 groups based on their UPSIT
676 scores with a score equal or less than 33 in males and 34 in females defining hyposmia⁶².

677 Results:

678 UPSIT scores in the normosmic group ranged from 34 to 28 (n=29 (21 women), age range [22-
679 73]). The hyposmic group had UPSIT scores ranging from 9 to 34 (n= 28 (21 women), age range:
680 [22-72]). CPT scores were significantly correlated with the UPSIT score ($\rho=0.377$, $P=0.004$) in
681 the whole group of participants. We found this correlation to be much stronger in the hyposmic
682 group ($\rho=0.702$, $P<0.001$).

683 **Conclusions:**

684 The CPT allows for distinction between normosmia and olfactory dysfunction with high sensitivity
685 and specificity. CPT scores are significantly correlated to UPSIT and Sniffin Sticks scores,
686 especially in a group of individuals with olfactory dysfunction.